MEDISTIM ASA (MEDI.OL) Stock Fundamental Analysis
OSL:MEDI - Euronext Oslo - NO0010159684 - Common Stock - Currency: NOK
MEDI gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 59 industry peers in the Health Care Equipment & Supplies industry. MEDI gets an excellent profitability rating and is at the same time showing great financial health properties. While showing a medium growth rate, MEDI is valued expensive at the moment. With these ratings, MEDI could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year MEDI was profitable.
MEDI had a positive operating cash flow in the past year.
Each year in the past 5 years MEDI has been profitable.
In the past 5 years MEDI always reported a positive cash flow from operatings.
1.2 Ratios
MEDI has a Return On Assets of 19.90%. This is amongst the best in the industry. MEDI outperforms 94.92% of its industry peers.
With an excellent Return On Equity value of 26.34%, MEDI belongs to the best of the industry, outperforming 94.92% of the companies in the same industry.
MEDI's Return On Invested Capital of 24.52% is amongst the best of the industry. MEDI outperforms 100.00% of its industry peers.
MEDI had an Average Return On Invested Capital over the past 3 years of 24.89%. This is significantly above the industry average of 8.57%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.9% | ||
| ROE | 26.34% | ||
| ROIC | 24.52% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
1.3 Margins
MEDI has a Profit Margin of 20.13%. This is amongst the best in the industry. MEDI outperforms 89.83% of its industry peers.
In the last couple of years the Profit Margin of MEDI has remained more or less at the same level.
With an excellent Operating Margin value of 25.92%, MEDI belongs to the best of the industry, outperforming 89.83% of the companies in the same industry.
MEDI's Operating Margin has been stable in the last couple of years.
MEDI has a better Gross Margin (80.46%) than 89.83% of its industry peers.
In the last couple of years the Gross Margin of MEDI has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.92% | ||
| PM (TTM) | 20.13% | ||
| GM | 80.46% |
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDI is creating value.
Compared to 1 year ago, MEDI has about the same amount of shares outstanding.
The number of shares outstanding for MEDI has been increased compared to 5 years ago.
Compared to 1 year ago, MEDI has a worse debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of MEDI is 0.19, which is an excellent value as it means it would take MEDI, only 0.19 years of fcf income to pay off all of its debts.
MEDI has a Debt to FCF ratio of 0.19. This is amongst the best in the industry. MEDI outperforms 96.61% of its industry peers.
MEDI has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.06, MEDI belongs to the top of the industry, outperforming 93.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.19 | ||
| Altman-Z | N/A |
ROIC/WACC2.88
WACC8.5%
2.3 Liquidity
A Current Ratio of 3.91 indicates that MEDI has no problem at all paying its short term obligations.
MEDI has a better Current ratio (3.91) than 88.14% of its industry peers.
A Quick Ratio of 2.52 indicates that MEDI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.52, MEDI is in the better half of the industry, outperforming 79.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
MEDI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.72%, which is quite good.
MEDI shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.96% yearly.
The Revenue has grown by 14.97% in the past year. This is quite good.
Measured over the past years, MEDI shows a quite strong growth in Revenue. The Revenue has been growing by 9.12% on average per year.
EPS 1Y (TTM)19.72%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%78.12%
Revenue 1Y (TTM)14.97%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%35.7%
3.2 Future
The Earnings Per Share is expected to grow by 6.19% on average over the next years.
MEDI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.35% yearly.
EPS Next Y-3.7%
EPS Next 2Y1.58%
EPS Next 3Y6.19%
EPS Next 5YN/A
Revenue Next Year10.05%
Revenue Next 2Y8.08%
Revenue Next 3Y7.35%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 29.06, the valuation of MEDI can be described as expensive.
66.10% of the companies in the same industry are more expensive than MEDI, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of MEDI to the average of the S&P500 Index (26.34), we can say MEDI is valued inline with the index average.
A Price/Forward Earnings ratio of 31.14 indicates a quite expensive valuation of MEDI.
MEDI's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, MEDI is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.06 | ||
| Fwd PE | 31.14 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDI is on the same level as its industry peers.
77.97% of the companies in the same industry are more expensive than MEDI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.58 | ||
| EV/EBITDA | 18.71 |
4.3 Compensation for Growth
MEDI has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.65
EPS Next 2Y1.58%
EPS Next 3Y6.19%
5. Dividend
5.1 Amount
MEDI has a Yearly Dividend Yield of 3.06%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.07, MEDI pays a better dividend. On top of this MEDI pays more dividend than 89.83% of the companies listed in the same industry.
MEDI's Dividend Yield is a higher than the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.06% |
5.2 History
On average, the dividend of MEDI grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
MEDI's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DPN/A
EPS Next 2Y1.58%
EPS Next 3Y6.19%
OSL:MEDI (6/18/2025, 7:00:00 PM)
195
+5 (+2.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners57.37%
Inst Owner ChangeN/A
Ins Owners2.83%
Ins Owner ChangeN/A
Market Cap3.58B
Analysts82.5
Price Target215.22 (10.37%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.06% |
Yearly Dividend4.5
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.67%
PT rev (3m)22.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.06 | ||
| Fwd PE | 31.14 | ||
| P/S | 5.86 | ||
| P/FCF | 25.58 | ||
| P/OCF | 25.58 | ||
| P/B | 7.67 | ||
| P/tB | 8.88 | ||
| EV/EBITDA | 18.71 |
EPS(TTM)6.71
EY3.44%
EPS(NY)6.26
Fwd EY3.21%
FCF(TTM)7.62
FCFY3.91%
OCF(TTM)7.62
OCFY3.91%
SpS33.28
BVpS25.43
TBVpS21.96
PEG (NY)N/A
PEG (5Y)3.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.9% | ||
| ROE | 26.34% | ||
| ROCE | 31.82% | ||
| ROIC | 24.52% | ||
| ROICexc | 38.86% | ||
| ROICexgc | 48.75% | ||
| OM | 25.92% | ||
| PM (TTM) | 20.13% | ||
| GM | 80.46% | ||
| FCFM | 22.91% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
ROICexc(3y)39.99%
ROICexc(5y)39.99%
ROICexgc(3y)48.52%
ROICexgc(5y)48.01%
ROCE(3y)32.29%
ROCE(5y)33.19%
ROICexcg growth 3Y-6.52%
ROICexcg growth 5Y0.36%
ROICexc growth 3Y-8.47%
ROICexc growth 5Y0.04%
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
F-Score5
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.19 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 76.53% | ||
| Profit Quality | 113.78% | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z | N/A |
F-Score5
WACC8.5%
ROIC/WACC2.88
Cap/Depr(3y)105.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.78%
Cap/Sales(5y)N/A
Profit Quality(3y)91.83%
Profit Quality(5y)103.03%
High Growth Momentum
Growth
EPS 1Y (TTM)19.72%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%78.12%
EPS Next Y-3.7%
EPS Next 2Y1.58%
EPS Next 3Y6.19%
EPS Next 5YN/A
Revenue 1Y (TTM)14.97%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%35.7%
Revenue Next Year10.05%
Revenue Next 2Y8.08%
Revenue Next 3Y7.35%
Revenue Next 5YN/A
EBIT growth 1Y21.63%
EBIT growth 3Y4.07%
EBIT growth 5Y7.86%
EBIT Next Year10%
EBIT Next 3Y10.15%
EBIT Next 5YN/A
FCF growth 1Y52.5%
FCF growth 3Y-0.65%
FCF growth 5Y12.16%
OCF growth 1Y52.5%
OCF growth 3Y3.75%
OCF growth 5Y12.23%